TY - JOUR
T1 - Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
AU - Saberi Hosnijeh, Fatemeh
AU - van der Straten, Lina
AU - Kater, Arnon P.
AU - van Oers, Marinus H. J.
AU - Posthuma, Ward F. M.
AU - Chamuleau, Martine E. D.
AU - Bellido, Mar
AU - Doorduijn, Jeanette K.
AU - van Gelder, Michel
AU - Hoogendoorn, Mels
AU - de Boer, Fransien
AU - te Raa, G. Doreen
AU - Kerst, J. Martijn
AU - Marijt, Erik W. A.
AU - Raymakers, Reinier A. P.
AU - Koene, Harry R.
AU - Schaafsma, Martijn R.
AU - Dobber, Johan A.
AU - Tonino, Sanne H.
AU - Kersting, Sabina S.
AU - Langerak, Anton W.
AU - Levin, Mark-David
PY - 2020/9
Y1 - 2020/9
N2 - Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology. Median event-free survival (EFS) was 23 months (range: 1.25–60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27 (>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter EFS than those with marker levels below the median. The effect of sCD23 on EFS differed between immunoglobulin heavy chain variable gene-mutated and unmutated patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above the median. Taken together, our results validate the prognostic impact of sCD23 and highlight SPINT1 and LY9 as possible promising markers for treatment response in CLL patients.
AB - Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology. Median event-free survival (EFS) was 23 months (range: 1.25–60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27 (>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter EFS than those with marker levels below the median. The effect of sCD23 on EFS differed between immunoglobulin heavy chain variable gene-mutated and unmutated patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above the median. Taken together, our results validate the prognostic impact of sCD23 and highlight SPINT1 and LY9 as possible promising markers for treatment response in CLL patients.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089975568&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/32781097
UR - http://www.scopus.com/inward/record.url?scp=85089975568&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.exphem.2020.08.002
DO - https://doi.org/10.1016/j.exphem.2020.08.002
M3 - Article
C2 - 32781097
SN - 0301-472X
VL - 89
SP - 55-60.e6
JO - Experimental Hematology
JF - Experimental Hematology
ER -